Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,900 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06548412RecruitingPhase 1/Phase 2
New drug combo for first-line treatment of advanced bile duct cancer
This trial tests a new drug called CTX-009 combined with three standard chemotherapy drugs (gemcitabine, cisplatin, and durvalumab) as a first treatment for bile duct cancer that cannot be removed by surgery or has spread. It aims to see if this combination is safe and effective.
Houston, TexasAges 18 years+ - NCT05526924RecruitingPhase 1
Phase 1 trial tests re-radiation plus immunotherapy and a cancer pill
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
Chicago, IllinoisAges 18 years+ - NCT06190886RecruitingPhase 1
First-in-human study of PTX-912 for advanced solid tumors
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT04215731RecruitingPhase 3
Chemo plus targeted drug before surgery for high-risk rectal cancer
This trial tests giving chemotherapy (mFOLFOXIRI) plus bevacizumab before surgery for rectal cancer that has higher-risk features. It aims to shrink or control the cancer early to improve outcomes after treatment.
Guangzhou, GuangdongAges 18–70 - NCT07763301RecruitingPhase 1
Vaccine for advanced liver, bile duct, or pancreatic cancer
This trial is testing an investigational vaccine (YMN-136) for people with advanced liver, bile duct, or pancreatic cancer that has not responded to standard treatments or is not tolerated. The vaccine aims to help your immune system fight the cancer. It may be an option if standard treatments have failed.
Chengdu, SichuanAges 18–75 - NCT06957886RecruitingPhase 3
Study of BL-M07D1 vs chemo for HER2-low breast cancer
This trial tests a new drug, BL-M07D1, against standard chemotherapy for people with HER2-low breast cancer that has spread or come back. It aims to find which treatment works better.
Guangzhou, GuangdongAges 18–75 - NCT06313086RecruitingPhase 3
New drug vs. T-DM1 for HER2-positive advanced breast cancer
This trial tests a new antibody-drug conjugate (DP303c) against an existing one, T-DM1, in people with HER2-positive advanced breast cancer who have already been treated with trastuzumab and a taxane. The goal is to see if the new drug works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06595563RecruitingPhase 2
PET imaging to guide HER2 breast cancer treatment sequencing
This study tests whether a special PET scan using a radioactive tracer can help doctors choose the right sequence of antibody-drug conjugates for HER2-positive advanced breast cancer. It is for patients whose cancer has already progressed on the drug T-DXd (Enhertu).
Anderlecht, Brussels CapitalAges 18 years+ - NCT06085664RecruitingPhase 1/Phase 2
Immunotherapy before prostate cancer surgery
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
Houston, TexasAges 18 years+ - NCT06434610RecruitingPhase 2
Study of B013 plus paclitaxel for ovarian cancer
This study tests a new drug (B013) combined with a standard chemotherapy (paclitaxel) for people with ovarian cancer that has come back after platinum-based treatment. The goal is to see if the combination works better than the current options.
BeijingAges 18–75 - NCT06121700RecruitingPhase 2
Chemoimmunotherapy and radiation before surgery for limited spread stomach cancer
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
ShanghaiAges 18–75 - NCT06234423RecruitingPhase 1
A study of CUSP06 for advanced solid tumors
This study tests a new drug called CUSP06 for people with advanced solid tumors, especially ovarian cancer that has stopped responding to platinum chemotherapy. It may help if standard treatments no longer work.
Denver, ColoradoAges 18 years+ - NCT06336902RecruitingPhase 1
Immunotherapy plus fasting diet and vitamin C for KRAS-mutated colorectal cancer
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) plus a fasting-mimicking diet and high-dose vitamin C for people with a specific type of advanced colorectal cancer (KRAS-mutated). It aims to see if this approach can help when standard treatments have stopped working.
Fullerton, CaliforniaAges 18 years+ - NCT07108127RecruitingPhase 2
Targeted drugs plus chemo for HER2-positive rectal cancer
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
BeijingAges 18 years+ - NCT07349069RecruitingPhase 3
HRS-8080 vs. standard hormone therapy for early breast cancer
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
Nanjing, JiangsuAges 18–75 - NCT05753826RecruitingPhase 2
Study of two medicines for platinum-resistant ovarian cancer
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
FujianAges 18–70 - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT05724745Recruiting
3D lung breathing test during MRI versus standard spirometry
This study compares a new 3D MRI-based breathing test with the usual breathing test called spirometry. It may help doctors measure lung function more precisely in healthy people and in people with asthma, COPD, or after a double lung transplant.
Orsay, FranceAges 18–90 - NCT06411691RecruitingPhase 1
Vaccine plus immunotherapy for KRAS-mutant cancers
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
Baltimore, MarylandAges 18 years+ - NCT06236139RecruitingPhase 1/Phase 2
Immune cells plus hormone therapy for advanced prostate cancer
This study tests a new type of treatment that uses your own immune cells (engineered to target prostate cancer) combined with a hormone therapy drug. It is for men with advanced prostate cancer that has stopped responding to standard hormone treatments.
Seattle, WashingtonAges 18 years+ - NCT07644559RecruitingPhase 2
VS-7375 for KRAS G12D pancreatic cancer
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT04823897RecruitingPhase 1
Testing CCI-001 alone and with chemo for recurrent solid tumors
This early study tests whether CCI-001 can be given safely and may help shrink or control recurrent or metastatic (advanced) solid cancers. It checks the right dose first, then studies CCI-001 with standard chemotherapy in certain cancer types.
Edmonton, AlbertaAges 18 years+ - NCT06710158RecruitingPhase 1
SC-102 for advanced solid tumors
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,900 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.